BioPharm America EBD Group Massachusetts Biotechnology Council BioPharm America
Share:
Email this page Share this on LinkedIn Share this on Twitter | print this page

BioPharm America™ 2014 Program Overview

The preliminary program for BioPharm America™ 2014 will be available soon

BioPharm America 2013 program

www.ebdgroup.com/bpa/program
Monday, September 16, 2013
6:00–8:00 pm
BioPharm America Welcome Reception

All BioPharm America attendees are cordially invited to join us for a welcome reception.

Sauciety, Lobby Level
Westin Boston Waterfront Hotel
425 Summer Street
Boston, MA 02210 (map)

You will be able to pick up your name badge at the welcome reception.

Tuesday, September 17, 2013
7:30 am
Grand Ballroom Level
7:30 am
Exhibit Hall, Grand Ballroom Level
Exhibition opens and Continental Breakfast
9:00–10:30 am
Parallel Workshops
The perfect pitch: Do you have what it takes to win over investors?

Tuesday, 9:00–10:30 am
Grand Ballroom E, Grand Ballroom Level

Win a one-to-one meeting with a leading life science private equity investor. Members of the audience will have 30 seconds to pitch their company, product, technology or service to a star-studded panel of judges representing at least six life science investment firms. The top picks will be selected for a second round that includes two minutes of presentation and/or Q&A time with the judges. First and second place winners will receive a full 30-minute private follow-up meeting with the panelist of their choice. Judges will receive a written summary of all participant pitches and their scores, should they wish to follow up on their own. Audience preparation notes:

Participants will be judged on the quality and effectiveness of the overall 30-second pitch. Remember, the primary goal of an elevator pitch is to spark interest for a follow-up meeting. Pre-workshop coaching is available from the moderator (contact: doug@macbiocom.com). Practice, practice, practice!

Moderator:
Douglas MacDougall – President, MacDougall Biomedical Communications

Judges:
  • Bernard Davitian – VP, BD and Structured Investments, Sanofi
  • Brian Gallagher, Jr. – Partner, SR One
  • Kevin Johnson – Partner, Index Ventures
  • Dennis Purcell – Senior Managing Partner, Aisling Capital
  • Sander van Deventer – General Partner, Forbion Capital Partners
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Why can't big pharma invest in my company?

Tuesday, 9:00–10:30 am
Commonwealth B, Grand Ballroom Level

Big pharma companies today are "balance sheet rich but P&L poor." They would like to invest in startup biotechnology companies in order to foster innovation and have access to new drugs. Investment by pharma companies in biotechnology companies could help fill the void left by vanishing venture capital and a lackluster IPO market. But if pharma companies are required to consolidate their investments, then the development spend of their startup investees hits the pharma P&L and R&D budgets.

In the good old days, a pharma company could avoid consolidating an investment in a biotechnology company if it owned less than 20% of the equity. But today, in the wake of the Enron debacle, the rules for consolidation are much more complex. Today, FIN 46 sets forth guidelines for the consolidation of "variable interest entities." This panel of industry experts will explore the landscape of pharma investment and consolidation, and examine how different pharma companies have come to very different conclusions about the requirement to consolidate, and what thresholds trigger that decision.

Moderator:
David Collier – CEO, Velocity Pharmaceutical Development

Panelists:
  • Sara Elinson – Principal, Deloitte Financial Advisory Services LLP
  • Tim Gordon – Partner, Americas FAAS, Life Sciences Leader, Ernst & Young
  • Kareem S. Reda – Associate Director, Business Development, Celgene
  • Atul Saran – VP, Corporate Development and Ventures, AstraZeneca
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:45 am–12:30 pm
Harbor Ballroom Level
Welcome, Keynote, and Opening Plenary Discussion
Welcome remarks

Tuesday, 10:45–11:15 am
Harbor Ballroom Level
 Speakers:
  • Carola Schropp – Founder, EBD Group
  • Robert K. Coughlin – President and CEO, MassBio
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Keynote Address

Harbor Ballroom Level
 Speaker:
  • Peter Sorger – Otto Krayer Professor, Department of Systems Biology, Harvard Medical School
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Strategic R&D planning: The chameleon Rubik's Cube

Tuesday, 11:15 am–12:30 pm
Harbor Ballroom Level

Long-term pipeline planning in drug development is like a Rubik's cube that changes colors as its surroundings do. How can companies make better strategic decisions despite the disconnect between decade-long R&D timelines and the ever-changing demands among payers and patients? How are these different organizations addressing regulatory and reimbursement challenges to bring better drugs to patients?

Moderator:
Vaughn Kailian – Managing Partner, MPM Capital

Panelists:
  • Richard J. Gregory – Head, Genzyme R&D Center, Sanofi R&D
  • Philippe Lopes-Fernandes – VP and Head, Global Business Development , Merck Serono
  • John Maraganore – CEO, Alnylam
  • Barbara Yanni – VP and Chief Licensing Officer, Merck
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:30–1:30 pm
Grand Ballroom Level
Luncheon
1:30–5:00 pm
Parallel Roundtable Discussions
The Future of Dealmaking
From discovery to early stage drug development: At the intersection of academia, biotech and pharma

Tuesday, 1:30–2:30 pm
Grand Ballroom E, Grand Ballroom Level

Increasing pressure to heighten productivity and lower cost has led many pharma companies to completely rethink their R&D and commercialization strategies. The resulting discovery and early stage drug development collaborations with academia are more popular than ever. Mutually aligned interests aside, how do these groups overcome their key differences to make it work? This panel will bring pharma, biotech and academic players together to discuss how they traverse the (sometimes bumpy) road to successful partnerships.

Chair:
Jeffrey L. Quillen – Partner, Foley Hoag LLP

Discussion leaders:
  • Laura Brass – Director of Business Development, Harvard University
  • Erik Halvorsen – Executive Director, Technology and Innovation Development Office; Managing Partner, Technology Development Fund, Boston Children's Hospital
  • Steven Tregay – Founder, President and CEO, Forma Therapeutics
  • Robert Urban – Head, Johnson & Johnson Boston Innovation Center
  • Robin Wright – CFO, Karolinska Development AB
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Partnering: Thinking beyond the deal

Tuesday, 2:45–3:45 pm
Grand Ballroom E, Grand Ballroom Level

When a speaker at a recent conference asked a room full of biotech executives who among them was planning to build a commercial company, one lonely hand went up. Is it impossible these days to become "the next Genentech/Amgen/ Biogen Idec"? If so, what are the reasons and what are the consequences? Is big pharma profiting by dictating deal terms that would not have been acceptable in the "good old days"? Are today's biotech-pharma partnerships struck (and timed) strategically or out of despair? When is the right time/situation to partner? We will discuss these questions and have a look at some of the partnering data to support or oppose some conclusions.

Chair:
Ed Saltzman – President, Defined Health

Discussion leaders:
  • Stéphane Bancel – President and Founding CEO, Moderna Therapeutics
  • Philippe Lopes-Fernandes – VP and Head, Global Business Development, Merck Serono
  • Kush Parmar – Principal, 5AM Ventures
  • Christoph Pittius – VP, Strategic Partnering and Business Development, Cardiovascular/Metabolic, AstraZeneca
  • Jason Rhodes – President and CFO, Epizyme, Inc.
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Virtual development companies: Innovation engines or empty shells?

Tuesday, 4:00–5:00 pm
Grand Ballroom E, Grand Ballroom Level

Why are virtual business models so popular these days? Are they actually the better models, or—with less venture money available and shorter investment periods—simply the only option for most biotechs in today's environment? Are management and employees of a virtual company able to develop great science and build a "real" enduring company capable of nimble decision making and action using a virtual model, or are they just focused on a quick-flip? Join executives from biotech and the investment community and discuss these and other questions around lean biotech business models.

Chair:
Christopher J. Denn – Partner, Life Sciences, Goodwin Procter

Discussion leaders:
  • Sheila DeWitt – President and CEO, DeuteRx LLC
  • Michael Gilman – Former Founder and CEO, Stromedix
  • Daniel Lynch – Venture Partner, Third Rock Ventures
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
External and Internal Drivers
Milestones or millstones: How to build and manage a functioning board for a biotech

Tuesday, 1:30–2:30 pm
Commonwealth C, Grand Ballroom Level

A productive and functional board is crucial to the success of a young company. The leaders of this discussion are experienced board members and/or company executives. Exchange your experiences on why a board can be either highly functional or dysfunctional, get advice on how to assemble a productive board, and hear war stories from the boardroom.

Chair:
Carol Greve-Philips – CBO, Pronota

Discussion leaders:
  • Alan Crane – General Partner, Polaris Partners
  • Kevin Johnson – Partner, Index Ventures
  • D. Kevin Kwok – Managing Director and Head, North American Pharma/Biotech, Russell Reynolds Associates
  • Lee McCracken – Former President and CEO, Pathwork Diagnostics
  • Catherine Angell Sohn – Board Member, Landec Corporation (Lifecore Biomedical LLC subsidiary)
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
How far can you go with angel investors?

Tuesday, 2:45–3:45 pm
Commonwealth C, Grand Ballroom Level

Over recent years a strong and flourishing angel community has sprung up in Boston. Individuals or groups of angel investors are funding companies with up to USD 60–70 million, making VC investments for these companies obsolete. How far can you go with an angel investor base these days? What are the advantages of angel versus VC investment? Do they mix? We will discuss with angel-funded companies their operating methods, hear from VCs whether they see angels as competitors, and learn some advantages and downfalls of this model.

Chair:
Mark Leuchtenberger – President and CEO, Acusphere

Discussion leaders:
  • Jeff Arnold – President, Arnold Strategies, LLC
  • Stephen J. Hoffman – Managing Director, Skyline Ventures
  • Walter Ogier – CEO, Acetylon Pharmaceuticals, Inc.
  • Todd Zion – President and CEO, Akston Biosciences Corp.
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Advancements in regulatory science: What are the implications for preclinical and clinical development?

Tuesday, 4:00–5:00 pm
Commonwealth C, Grand Ballroom Level

Breakthroughs in regulatory science will have a profound impact on how we develop drugs in the future and on the investment decisions we make to support new programs and protocols. This roundtable will discuss some of the key challenges and requirements around innovative regulatory approaches and technologies, including adaptive trial design and the harnessing of data to improve health outcomes. As the regulatory system evolves to implement these new capabilities, there will likely be a profound impact on how stakeholders understand and interpret results at different points along the development continuum. This discussion will include several experts in the field of regulatory science in addition to industry leaders advancing efforts to bring these new capabilities into standard practice.

Chair:
Karen Becker – Managing Director, Regulatory Sciences, Precision for Medicine

Discussion leaders:
  • Peter Honig – Head, Global Regulatory Affairs, Patient Safety, and Quality Assurance, AstraZeneca
  • Garry Neil – Partner, Apple Tree Partners; Chairman, TransCelerate BioPharma, Inc.
  • Karin Van Baelen – Head Global Regulatory Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Therapeutic Spotlight
Ultra orphan drugs: Development, business model, pricing, reimbursement

Tuesday, 1:30–2:30 pm
Commonwealth B, Grand Ballroom Level

The days when only a few niche players tackled orphan diseases are over. An abundance of opportunities, few competitors in the respective areas as well as innovative regulatory and pricing approaches have whetted pharma's appetite for orphan indications. What types of business models work in indications with very small patient populations? Can these models work for large pharma? In fact, should pharma be spending money and resources on ultra orphan indications? Is this an area where biotech should "go it alone"?

Chair:
Jim Geraghty – Entrepreneur-in-Residence, Third Rock Ventures and Chairman, Idera Pharmaceuticals

Discussion leaders:
  • Steve Aselage – Independent Consultant, QLT and SERC; Board of Directors, Retrophin
  • Roger Garceau – Executive VP and Chief Medical Officer, NPS Pharmaceuticals
  • Nick Leschley – chief bluebird, bluebird bio
  • Jonathan Montagu – VP, Business Development and Operations, Nimbus Discovery, Inc
  • Jeff Poulton – Rare Disease Business Unit Head (interim), Shire Pharmaceuticals
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Regenerative medicine and advanced therapies: What types of partnerships will they require to achieve commercial success?

Tuesday, 2:45–3:45 pm
Commonwealth B, Grand Ballroom Level

The field of regenerative medicine—in Europe referred to as advanced therapies—also including gene therapy and cell-based immunotherapies, is gaining momentum with a large number of novel and potentially transformative products moving into late-stage clinical development. Indeed, some of these therapies are already on the market for indications such as wound healing and GvHD. Many of them have characteristics relating to their manufacture, distribution, administration, and delivery that take them outside of existing commercialization models, while others can be developed along more traditional paths. Some of them require a different way of thinking about regulatory and reimbursement requirements, but the results could mean a more rational and effective way of treating disease. During this session, key stakeholders and new players in therapeutic development will discuss the types of partnerships that will sustain and guide this field as it continues to mature.

Chair:
Gil Van Bokkelen – Chairman and CEO, Athersys, Inc.

Discussion leaders:
  • Geoff MacKay – President and CEO, Organogenesis
  • John McNeish – Head of Research, Regenerative Medicine DPU, GlaxoSmithKline
  • Brock Reeve – Executive Director, Harvard Stem Cell Institute
  • Morrie Ruffin – Managing Partner, Adjuvant Partners
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
CNS: Trials, tribulations and the journey to the pot of gold

Tuesday, 4:00–5:00 pm
Commonwealth B, Grand Ballroom Level

The large CNS indications, especially those related to aging, are among the most intractable and costly diseases and present tremendous challenges to patients, payers and society. Despite the indisputable medical unmet need, the life science industry has made little headway in improving patient outcomes in these diseases. Why have so many experimental drugs for neurodegenerative disorders failed? How can industry work together to bring forward more promising drug candidates and to manage the risk of these often large and expensive trials? How can biotechs drive innovation in this area, if most VCs won't touch CNS indications with a ten-foot pole? Are recent pharma-to-pharma collaborations the light at the end of the tunnel? For this session we will assemble leaders from biotech, pharma, venture capital, academia and patient advocacy for a productive discussion on new R&D and business models in CNS indications.

Chair:
Richard Brudnick – VP, Co-Head BD/M&A, Biogen Idec

Discussion leaders:
  • Martin Jefson – CSO, Rodin Therapeutics
  • Kiran Reddy – Interim Chief Business Officer, SAGE Therapeutics
  • Dale Schenk – CEO, Prothena
  • David Silbersweig, MD – Chairman, Department of Psychiatry, Co-Director, Institute for the Neurosciences, Brigham and Women's Hospital; Stanley Cobb Professor of Psychiatry, HMS Dean for Academic Programs, Partners Healthcare, Harvard Medical School
  • Kumar Srinivasan – VP, Scientific Partnering and Alliances, AstraZeneca
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Welcome to the Digital Age
Leveraging big data to discover and develop breakthrough treatments

Tuesday, 1:30–2:30 pm
Commonwealth A, Grand Ballroom Level

We are living in the era of big data in healthcare, with unprecedented ability to collect data at multiple levels (molecular/'omic', phenotypic, and transactional) and at scale. This has the potential to transform our fundamental understanding of diseases for which we have few effective treatment options. We aim to discuss the potential of big data in reshaping how we discover new treatments, the challenge in collecting this data, and how we transform it into knowledge that would lead to new and effective treatment options for patients.

Chair:
Iya Khalil – Executive VP and Co-Founder, GNS Healthcare

Discussion leaders:
  • Pamela Carroll – VP, Oncology Scientific Innovation, Janssen Pharmaceutical Companies of Johnson & Johnson
  • Joel Dudley – Director of Biomedical Informatics, Mount Sinai School of Medicine
  • Magali Haas – Founder and CEO, Orion Bionetworks
  • Stanley Shaw – Co-Director, Chemical Biology, MGH Center for Systems Biology; Co-Founder, Co-Director, MGH Center for Assessment Technology and Continuous Health (CATCH)
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
A new era: The melding of drugs, devices and information

Tuesday, 2:45–3:45 pm
Commonwealth A, Grand Ballroom Level

Chair:
Daphne Zohar – Founder, Managing Partner, PureTech Ventures

Discussion leaders:
  • Rajni Aneja – Strategic Executive and Clinical Transformation Leader, Humana
  • Frank Moss – Co-Founder, Atelion Health and Matter.io
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
The power of the patient in drug development

Tuesday, 4:00–5:00 pm
Commonwealth A, Grand Ballroom Level

The impact of the patient on the development of treatments and cures is rapidly evolving. Simultaneously the confluence of electronic medical records and big data is changing the way in which information is being generated. This panel will examine the new roles patients and patient groups are assuming in the entire drug development process—from basic research to translational work and now a central role in clinical trial planning and execution and commercialization. The recent emergence of crowd funding is also starting to impact the ability of patients to fund research projects directly at both academic and commercial labs. Moreover, philanthropic crowd funding of commercial translational drug development is allowing patients to direct their donations to drugs poised to enter the market, not just the clinic. This trend is set to spread broadly once the Non-Accredited investor regulations are issued. This roundtable will explore all of these issues with some of the leading experts from the patient and crowd funding communities.

Chair:
Christine Copple – CEO, Starise Ventures, Inc.

Discussion leaders:
  • Mona Jhaveri – Founder and Executive Director, Beats of Laughter
  • Brian Loew – Founder and CEO, Inspire
  • Imran Nasrullah – Head, Strategic Alliances, T1D Exchange
  • Gregory C. Simon – CEO, Poliwogg Holdings, Inc.
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
5:15–6:15 pm
Plenary Discussion
Personalized medicine: The path to broader adoption

Tuesday, 5:15–6:15 pm
Harbor Ballroom Level

Efforts in personalized medicine are effectively creating genetically-defined sets of orphan diseases, enabling more effective therapies for patients. However, this poses substantial challenges in addressing appropriate R&D models, business models, regulatory frameworks, and reimbursement models that support the growth of personalized medicine. This panel will frame the challenges and explore potential solutions to facilitate the broader adoption of personalized medicine. What can we learn from the rare genetic disorder space and orphan drug space which are pioneering areas of personalized medicine? What R&D models will be necessary to support the development of therapies for smaller groups of patients but with better understanding of the genetic basis of their disease? What technologies are bringing efficiency into the R&D process and what new technologies will need to be developed? Will the reimbursement paradigm in the US be able to support a personalized medicine business model? How does the regulatory framework need to continue to evolve in order to support the development of personalized medicine therapies?

Moderator:
Chris Varma – President, CEO, and Co-Founder, Vision Medicines; Former President, CEO, and Co-Founder, Blueprint Medicines

Panelists:
  • Josh Boger – Founder, Director and Former CEO, Vertex Pharmaceuticals
  • Peter Hirth – Founder and Former CEO, Plexxikon
  • Peter Kolchinsky – Founding Partner and Portfolio Manager, RA Capital
  • Raju Kucherlapati – Principal Investigator, Kucherlapati Lab, Harvard Medical School
  • Christoph Lengauer – Chief Scientific Officer, Blueprint Medicines
  • Mark Levin – Partner, Third Rock Ventures
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
7:00–9:30 pm
Evening Networking Reception with Buffet-style Dinner
Museum of Science

Museum of Science
1 Science Park
Boston, MA 02114 | (map)

Enjoy an evening at the Museum of Science, a world-class museum with a vision to promote science, technology, engineering, and math (STEM) education.

Co-hosted by EBD Group and the Harvard Office of Technology Development, the event will bring together Biopharm America attendees, Harvard researchers and leaders, as well as investors and senior executives from the local Boston ecosystem. Harvard Technology "Masterpieces" will be displayed.

Co-hosted by:

EBD Group EBD Group Harvard University Harvard University

6:30–7:00 pm Shuttle buses will transport guests to the reception
8:45–9:30 pm Shuttle buses will transport guests to the Westin Boston Waterfront

Wednesday, September 18, 2013
7:30 am
Grand Ballroom Level
7:30 am
Exhibit Hall, Grand Ballroom Level
Exhibition opens and Continental Breakfast
9:30–10:30 am
Workshop
How to position your early stage company for success

Wednesday, 9:30–10:30 am
Stone, Lobby Level

For early stage biotech companies, attracting investors and potential partners is essential to running a successful business. Entrepreneurs and executives need to understand what VCs and pharma are looking for when they consider an investment or a partnership. This workshop will provide hands-on advice on some of the key areas to consider early on. This will include IP considerations and positioning, and the definition of goals and milestones for a company. During this session, experienced biotech executives will share how they position their company to be attractive for potential partners. You will also hear from pharma dealmakers about how to get their attention.

Moderator:
Sandra Kuzmich – Partner, Frommer, Lawrence & Haug LLP

Panelists:
  • Thomas Hanke – Director, Biopharmaceuticals Innovation Sourcing, Biopharm. Research Unit, Novo Nordisk
  • Arthur Hiller – CEO, SciFluor Life Sciences
  • Sanjeev K. Munshi – Director, External Scientific Affairs, Worldwide Licensing and Acquisition, Merck
  • Michael Weingarten – Director, NCI Small Business Innovation Research (SBIR) Development Center
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–6:00 pm
One-to-one Meetings ►
8:30–11:10 am
Pharma and Large Biotech Presentations

Wednesday, 8:30–11:10 am
Otis, Lobby Level

8:30 am – Merck
8:50 am – AstraZeneca
9:10 am – Bayer
9:30 am – Biogen Idec
9:50 am – EMD Serono
10:10 am – Johnson & Johnson Boston Innovation Center
10:30 am – Novo Nordisk
10:50 am – Shire

BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:15 am–12:30 pm
Company Presentations ►
11:00 am–12:00 pm
Roundtable Discussion
Social media in life sciences

Wednesday, 11:00 am–12:00 pm
Stone, Lobby Level

Social media has matured and now Twitter feeds and blog posts are the usual stock in trade of corporate communications. But how are dealmakers and executives making use of the maturing medium? Join us for a one-hour interactive roundtable discussion featuring several "tweet leaders" in social media from various sectors of life sciences: executives, reporters and investors. In particular, we will be exploring the "new normal" in life sciences as the industry discussion moves online. Questions to be addressed include:

  • What can and should executives be saying about their companies on social media?
  • When do tweets move stocks?
  • Which aspects of dealmaking and corporate dialogue will move online first? Which aspects have already moved online?
  • For life sciences companies and executives, does any other online platform matter besides Twitter?

Chair:
Steven Dickman – CEO, @cbtadvisors (1,483 followers)

Discussion leaders:
  • Katrine Bosley @ksbosley – Independent Director, Galapagos; Independent Board Member, Genocea (929 followers)
  • @adamfeuerstein – Sr. Columnist, TheStreet (24,590 followers)
  • @michael_gilman – Former Founder and CEO, Stromedix (2,726 followers)
  • @daphnezohar – Founder, Managing Partner, PureTech Ventures (3,053 followers)
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:30–1:30 pm
Grand Ballroom Level
Luncheon
12:30–1:30 pm
BaselArea Networking Lunch
Discover the most vibrant life science ecosystem in Europe

Discover the most vibrant life science ecosystem in Europe
Wednesday, 12:30–1:30 pm
Commonwealth C, Grand Ballroom Level

A panel of senior life science executives from Switzerland will focus on themes around how to do business in Switzerland. The panelists will talk about how startups in biotech and medical devices, established biotechnology companies and big pharma, can benefit from infrastructure such as R&D opportunities, access to innovation, intellectual property, and work force. Find out what needs to be considered when starting a life science company in or moving part of a business to the most vibrant life science cluster in Europe, and network with some of the movers and shakers of the Swiss life science industry.

Limited seating available. Please pre-register by email (events@baselarea.ch)

Moderator:
Patrik Frei – CEO, Venture Valuation

Panelists:
  • Patrick Ballmer – VP, CEO of Business Unit America, SOTAX Group
  • Ulf Grawunder – Founder and CEO, NBE Therapeutics
  • Gabriela Güntherodt – Director North America, BaselArea Economic Promotion
  • Ravi Sodha – Senior Director, Business Development, Actelion Pharmaceuticals Ltd.
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
1:30–4:30 pm
Company Presentations ►
4:30–5:30 pm
Keynote Panel
Who will be funding early stage biotech in the future?

Wednesday, 4:30–5:30 pm
Harbor Ballroom Level

Moderator:
Luke Timmerman – VP, Life Science Initiatives, Xconomy

Panelists:
  • Bruce Booth – Partner, Atlas Venture
  • Alexis Borisy – Partner, Third Rock Ventures
  • Jens Eckstein – President, SR One
  • Dennis Purcell – Senior Managing Partner, Aisling Capital
  • Gregory C. Simon – CEO, Poliwogg Holdings, Inc.
BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
5:30–6:45 pm
Exhibit Hall, Grand Ballroom Level
Exhibit Hall Hospitality Reception
Thursday, September 19, 2013
7:30 am
Grand Ballroom Level
7:30 am
Exhibit Hall, Grand Ballroom Level
Exhibition opens and Continental Breakfast
9:30–11:00 am
Academic Innovators™ Showcase

Academic Innovators™ Showcase
Thursday, 9:30–11:00 am
Hancock, Lobby Level

Join us for our inaugural Academic Innovators™ presentation track as we work with industry leaders to shine a spotlight on the many scientific advances with strong translational potential being made in the academic world.

Opening Remarks by:
Jeffrey S. Nye, MD, PhD – VP, Scientific Partnership Strategy and Neuroscience Innovation, Janssen R&D and Johnson & Johnson Innovation

Organizations:
  • Albert Einstein College of Medicine
  • Boston Children's Hospital
  • Cincinnati Children's Hospital Medical Center
  • Fundación MEDINA
  • New York University Medical Center
  • Sanford-Burnham Medical Research Institute

Following the presentations we invite you to join an interactive discussion with the Innovators.

BioPharm America™ 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–3:00 pm
One-to-one Meetings ►
8:30 am–12:30 pm
Company Presentations ►
12:30–1:30 pm
Grand Ballroom Level
Luncheon
3:00–4:00 pm
Exhibit Hall, Grand Ballroom Level
Closing Reception
Arrow Up


© 2009–2014 EBD Group, Inc.
BioPharm America EBD Group Massachusetts Biotechnology Council